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Abstract
Objective The typical histological features of chronic hepatitis
and cirrhosis are variable degreesof hepatocellular necrosis and
inflammation (activity or grade of disease), fibrosis (stage of
disease), and associated fat and iron deposition. These features
influence the liver’s appearance and must be assessed
separately by imaging biomarkers in order to be clinically
useful. Hepatic morphologic alterations and features of portal
hypertension identify most cases of established cirrhosis.
Nowadays, research is focused on developing ways to improve
detection of early and intermediate stages of fibrosis as well as
hepatocyte dysfunction. Even more, most imaging-related
measurements are subject to complex interactions and are
influenced by different pathologic processes, such as fatty
infiltration, edema, necrosis and iron accumulation.
Methods and results MR experience throughout the last
15 years at the Dr Peset University Hospital is reviewed.
Conclusion Nowadays, several biomarkers have been de-
veloped to grade the liver status in cirrhosis. This review
will focus on these topics.
Keywords Liver cirrhosis.Liver, MR imaging
Introduction
Hepatic cirrhosis is a chronic inflammatory liver disorder
associated with fibrosis. Although fibrosis is considered the
hallmark of cirrhosis, regeneration, necrosis and inflamma-
tion are important prognostic factors. Cirrhosis is also
frequently associated with steatosis, iron overload and
prominent vascular abnormalities.
The most relevant etiologic factors in cirrhosis are alcohol,
viruses, nonalcoholic steatohepatitis and hemochromatosis.
Initial clinical symptoms are vague, while advanced disease is
mainly associated to liver decompensation with ascites,
esophageal variceal hemorrhage, jaundice and hepatic enceph-
alopathy. The hepatocellular carcinoma (HCC) development
rate is 8% at 5 years and 25% at 10 years.
In most centers, patients with chronic hepatitis and cirrhosis
are initially biopsied to establish a definitive diagnosis and
stage the liver status. However, a biopsy is not necessary if the
clinical, laboratory and radiological data suggest cirrhosis.
Furthermore, there is a small but significant risk to liver biopsy,
and cirrhosis itself predisposes patients to complications due to
liver biopsy.
Magnetic resonance (MR) imaging is mostly used in the
diagnosis of tumor development because of its ability to
reliably depict HCC. The currently available imaging tests
(ultrasound, computed tomography and conventional MR
imaging) are neither sensitive nor specific in the detection of
early parenchymal changes. Many signs of moderate and
advanced cirrhosis can be detected as classical morphological
and signal intensity changes. New functional MR imaging
sequences can also depict fat and iron deposition, regenerative
nodules, necroinflammatory infiltrate, fibrosis, varices, perfu-
sion abnormalities and hepatocyte functionality [1, 2].
The evaluation of chronic hepatitis and cirrhosis with
imaging modalities should be performed ideally on early stages
of the disease. To be clinically useful, any method used to
evaluate chronic hepatitis and cirrhosis must accurately identify
regeneration, inflammation, necrosis, fibrosis, fat, iron and also
neoplasia. Fibrosis, necroinflammatory activity, fat and iron
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treatment indication and follow-up. Report and quantification
of these parameters by the radiologist are fundamental in order
to entail an impact on patient management.
MR technique
The protocol for MR evaluation of cirrhosis is heavily biased
towards HCC depiction. However, the different components of
the parenchymal lesions may also need to be studied and
quantitated. An all-in-one MR evaluation protocol should
include the following sequences.
High-resolution expiratory breath hold dual-echo chemical
shift spoiled gradient-echo (GRE) sequencing is used for the
acquisition of opposed-phase and in-phase T1-weighted(T1W)
images. The dual-echo sequence can evaluate fat, although the
use of T2* correction performs better for an accurate
quantification [3, 4]. This T2* calculation can be used to
measure iron accurately with a multiecho GRE sequence.
Respiratory triggered short T1 inversion recovery turbo spin
echo (STIRTSE) images should be optimized so that the signal
intensity of the liver is close to that of the subcutaneous fat and
paraspinal muscles (TI of 150–160 ms at 1.5-Tand 180–190 at
3-T magnets), which serve as an internal tissue of reference for
the necro-inflammatory activity.
Three-dimensional spoiled T1W GRE contrast-enhanced
dynamic examinations with fat suppression are mainly used to
exclude tumor development and grade esophageal varices.
Controlling the bolus arrival interval time for the late arterial,
portal and equilibrium phases is required. Maximum intensity
projection (MIP) vascular map images reconstructed from the
arterial and portal phases show the extent of collateral vessels
due to portal hypertension, as well as the arteries that perfuse
abnormal regions and lesions.
In order to calculate pharmacokinetic model parameters, the
acquisitionshouldhaveenoughtemporal resolution(less than5
s for each image set, for at least 5 min) with a dual input double
compartment model. A voxelwise statistical analysis is sug-
gested. This dynamic acquisition can be acquired with a low
dose of contrast media (a fifth of the regular dose) and also be
used to calculate the bolus arrival time to properly initiate the
late arterial phase of the high-resolution conventional dynamic
sequence.
The 3D high-resolution fat suppression T1W spoiled GRE
images obtained 30 to 60 min after the administration of
hepatobiliary contrast media (HBCM), although not routinely
used in the MR evaluation of cirrhosis and HCC development,
may give information on hepatocyte functionality.
The T2* GRE images obtainedafter superparamagnetic iron
oxide particle (SPIO) liver enhancement, with and without
concomitant gadolinium-based contrast-enhanced dynamic
images, can be used to rule out HCC in difficult cases and
depict advanced fibrosis. Specific contrast media with intracel-
lular phases may be used to differentiate perfusion abnormal-
ities from tumor development.
Although large vessels can be observed with most MR
images, the use of steady-state fully refocused transverse
magnetization GRE images (such as balanced, Fiesta or true-
FISP) facilitates the observation of abnormal parenchyma
vessels.
Diffusion-weighted (DW) imaging is an MR technique that
is based on intravoxel incoherent motion (IVIM) and provides
noninvasive quantification of water diffusion and
microcapillary-blood perfusion. Information provided with
DW reflects tissue cellularity, integrity of cellular membranes
and capillarity. In order to standardize DW acquisitions and
apparent diffusion coefficient (ADC) calculations, a biexpo-
nential signal modeling and respiratory-triggered precontrast
acquisitions with at least 5 b-values (0, 50, 200, 400 and
1,000 s/mm2) are suggested [5].
Imaging regeneration
Chronic hepatitis does not modify the macroscopic architecture
of the liver. On the other hand, advanced cirrhosis generates
typical morphological changes in the liver parenchyma and
surface contour because of regenerating nodules, necrosis and
fibrous development, which alter the liver architecture.
Liver surface nodularity is usually fine and diffuse, being
more prominent on the hypertrophied segments. Although the
finding has been claimed as characteristic, minor bulging of the
liver surface can be found in normal cases, and also hepatic
surface nodularity can be seeni np a t i e n t sw i t hf u l m i n a n t
hepatic failure, usually reflecting a combination of alternating
foci of confluent regenerative nodules and necrosis [6].
Regeneration and necrosis lead to liver global or segmental
volumetric changes associated with regional variations in the
portal venous bloodsupply[7]. Although any combination can
be found, the caudate lobe and lateral segment of the left
hepatic lobe usually develop hyperplasia, whereas the left
medial segment and right lobe show atrophic changes
(Fig. 1a). As a tendency, atrophy is most frequently seen in
alcohol-induced cirrhosis.
One of the first imaging biomarkers for diagnosing
cirrhosis was the evaluation of caudate lobe hyperplasia
with the caudate-right lobe ratio [8]. This index chose the
bifurcation of the main portal vein as a reproducible
landmark to divide these lobes. A ratio greater than 0.65
is associated with cirrhosis with an overall accuracy of
66%. The modified caudate-right lobe ratio uses the right
portal vein bifurcation to set the lateral boundary, with an
abnormal index being greater than 0.9. This index is more
accurate (74%) for diagnosing cirrhosis and evaluating its
clinical severity as significant differences were found
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[9].
Caudate hypertrophy is also responsible for the right
posterior hepatic notch sign, defined as a sharp indentation on
themedialposteroinferiorliversurfacebetweenthecaudateand
right lobes (Fig. 1b). The deeper the notch, the more advanced
the cirrhosis. This finding has a very high positive predictive
value [10].
Another associated finding related with segmental paren-
chyma atrophy is the widening of the porta hepatis demon-
strated as a prominent fatty space anterior to the main portal
vein at the hepatic hilum. The enlargement of the perichole-
cysticspace(Fig.2) bounded laterally by the right hepatic lobe
and medially by the lateral segment of the left hepatic lobe is
known as the expanded gallbladder fossa sign [11]. Again,
both signs have a high positive predictive value but much
lower sensitivity [12]. The umbilical fissure also widens with
the left lobe segmental atrophy. Although all these changes
must be considered specific for relatively advanced cirrhosis,
the enlargement of the hilar periportal space has been
demonstrated in early cirrhosis [11].
Most regenerative nodules are small. Macroregenerative
nodules rarely exceed 2 cm in diameter, and therefore larger
nodules should be carefully evaluated to exclude dysplasia and
carcinogenesis. Slightly hypovascularized large confluent areas
of regenerative nodules may be seen mainly close to the
interlobar and intersegmental territories.
Regenerative nodules are homogeneous, non-encapsulated,
hypointense, rounded foci on T2W images, whereas they are
usually isointense on T1W images. They are surrounded by
fine reticular septa, slightly hyperintense on fat-suppressed
T2WandSTIRimages(Fig.3). Markedly hypointense nodules
on the in-phase second echo GRE and T2W TSE images are
considered siderotic. Some non-dysplastic and non-tumoral
nodules may be hyperintense on the T1W GRE images
(Fig. 4), but they do not contain fat (do not lose signal
intensity on opposed-phase imaging) and are not arterialized
(do not significantly enhance during the hepatic arterial
dynamic phase). This high signal intensity in T1W images is
Fig. 1 Morphological changes of the liver. Transverse opposed-phase
T1W images show caudate hypertrophy with nodular surface and
prominent fat at the hepatic hilum (a). The right posterior hepatic
notch sign is clearly defined in another patient (b)
Table 1 The Child-Pugh score employs five clinical measures of liver disease. Each measure is scored 1–3, with 3 indicating the most severe
derangement. INR = international normalized ratio of prothrombine prolongation
Measure 1 point 2 points 3 points
Total bilirubin (μmol/l and mg/dl in brackets) <34 (<2) 34–50 (2-3) >50 (>3)
Serum albumin (g/l) >35 28–35 <28
INR <1.7 1.71–2.20 >2.20
Ascites None Mild Severe
Hepatic encephalopathy None Grade I–II (or suppressed with medication) Grade III–IV (or refractory)
Fig. 2 Morphological changes of the liver. Transverse in-phase T1W
image shows an expanded gallbladder fossa sign
Insights Imaging (2010) 1:233–244 235multifactorial, but mainly related to the intracellular glycogen
content [13].
Cirrhosis is not the only disease associated with morpho-
logical changes of the liver. Regeneration and atrophy can also
be found in disorders such as Budd-Chiari syndrome,
postchemotherapy, nodular regenerative hyperplasia and portal
cavernomatosis.
Imaging inflammation and necrosis
Standard T1W and T2W images are not sensitive to the
inflammatory liver changes. On the contrary, respiratory
triggered STIR TSE images depict an increase in liver
brightness when there is an increase in the water content due
to intracellular edema, inflammation or cell necrosis (Fig. 5).
This increased signal can be qualitatively assessed if the
inversion time T1 is properly adjusted so that the normal liver
signal intensity is quite similar to the signal of the paraspinal
muscles. In chronic hepatitis and cirrhosis, this increase in the
liver signal intensity can be considered a surrogate marker of
portal inflammation and periportal and lobulillar necrosis [14].
The liver signal in STIR images is not influenced by the
presence of either fibrosis or steatosis. However, the presence
of iron decreases the liver signal intensity and masks the
increased signal of the necroinflammatory infiltrates. If iron is
present, the necroinflammatory activity cannot be properly
estimated with TSE-STIR images.
Reactive lymph nodes at the hepatic hilus and gastrohepatic
ligament are also well-known findings. Lymphadenopathy
occurred more frequently in autoimmune and virus-induced
cirrhosis. Superior diaphragmatic adenopathies are usually
hyperplastic, even when an HCC is present (Fig. 6). A
prominent cisterna chyli, with a diameter larger than 2 mm,
is observed in uncompensated cirrhosis with a high positive
predictive value of 96%. This phenomenon is due to the
increased lymph production in these patients caused by
disturbance in the drainage of vascular flow from the sinusoid
to the central or terminal hepatic veins associated with lobular
distortion-impaired lymphatic circulation in cirrhosis [15].
Late arterial phase dynamic contrast-enhanced MR images
may demonstrate a heterogeneous pattern of patchy parenchy-
mal enhancement with large geographical areas showing a
slight hypovascularization [16]. This frequent finding (50%)
of perfusion heterogeneity relates to the presence of inflam-
matory macrophages, variable hepatocyte necrosis and in-
creased steatosis. These areas may progress to areas of focal
confluent fibrosis and collapse [17].
Fig. 3 Fibrosis and regenerative nodules. Transverse STIR image
shows a reticular pattern of the fibrotic bands surrounding hypointense
regenerative nodules
Fig. 4 Non-tumoral nodules. Transverse opposed (a) and in-phase (b)
T1W images show hyperintense nodules without decreased signal
intensity on opposed-phase imaging and hypointensity on STIR image
(c). Note several Gamna-Gandy siderotic splenic bodies due to
advanced portal hypertension
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heterogeneous enhancement relates to the presence of
hepatocyte necrosis intermixed with fibrous bands. Areas of
regenerationdemonstrate anincreasedenhancement relatedto
the increase in the number of hepatocytes per voxel together
with an impaired bile excretion [18]. In cirrhosis, the severity
of the hepatic injury relates to the down-regulation of the
HBCM transporter expression, leading to a threshold
response appearing in advanced stages (much lower en-
hancement), but not before (relative maintained enhance-
ment). With this limitation in mind, the Gd-EOB-DTPA
hepatic extraction fraction can be used as a direct,
noninvasive technique for the quantitative evaluation of liver
function. This extraction ratio is calculated from deconvolu-
tion analysis of aortic and hepatic parenchymal time-
intensity curves obtained by dynamic MRI and could be a
promising alternative for the determination of noninvasive
hepatic function in patients with liver disease [19].
OntheT2*WGREimagesacquiredwithalongTE(≈7ms),
the less hypointense areas are statistically related to reduction in
their functional status. Heterogeneous R2* shortening is also a
reliable predictor of advanced fibrosis (Fig. 7), with a positive
predictive value of 93%. Unfortunately, SPIO measurements
are insensitive to early and moderate abnormalities. Iron oxide
particles will clearly depict the fibrotic bands surrounding the
hypointense negatively enhanced regenerative nodules [20].
Inanearlystudyinpatientswithliverbiopsy,ADCwasnot
correlated with inflammation grades [21]. However, more
recent publications [22, 23] have shown a significant
relationship between ADC and inflammation scores, with
ADC being a predictor of inflammation grade 1 or greater.
Unfortunately, ADC values are influenced by the choice of
b-value; they are multifactorial (steatosis, fibrosis, perfusion)
and vary between different vendors, limiting the role of
standard ADC calculations.
Imaging fibrosis
Routine MR imaging cannot observe early fibrosis, but these
images are sensitive for detecting moderate and advance
fibrosis by demonstrating the reticular pattern of the fibrotic
bands surrounding regenerative nodules. This fine reticulation
is hyperintense on T2W fat-suppressed images and on the
equilibrium and delayed images after contrast administration
(Fig. 8). This appearance is due to the coexistence of
inflammation in these fibrotic a r e a s .T h ef i n es i e v ea p p e a r -
ance, occasionally associated with poorly defined subcapsular
retractile stellate areas, are clear indicators of the presence of
advanced fibrosis. Confluent mass-like lesions may also be
depicted. The observation of this pattern is facilitated by
decreasing the signal intensity of the nodules after SPIO
administration while increasing the signal from the septa after
gadolinium enhancement [2]. This double contrast technique
has been shown to be accurate for advanced fibrosis [24].
Although this method separates advanced fibrosis or cirrhosis
(F3–F4) from intermediate, early or no fibrosis (F2-F0), it
Fig. 6 Reactive lymph node. Transverse STIR image shows lymph-
adenopathy at the gastroduodenal and retroperitoneal areas. Note the
increased signal intensity of the liver due to necroinflammatory
activity
Fig. 5 Inflammation and necrosis. Transverse STIR image shows an
increase in liver brightness due to intracellular edema, inflammation
and necrosis Fig. 7 Fibrosis. Liver heterogeneous decreased enhancement after
SPIO is related to the presence of fibrous bands and subcapsular
collapse areas
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minimal (stage F1) and intermediate (stage F2) fibrosis.
Areas of focal confluent fibrosis are usually found in long-
standing cirrhosis, especially associated with alcohol abuse.
They are frequently multiple, with the most classical locations
being the interlobar and intersegmental fissures, as these areas
have terminal territory perfusion. The collapsed area has a
geometrical (often triangular or quadrilateral) capsular-based
wedge shape pointing to the hepatic hilum, associating volume
loss and capsular retraction with focal flattening or even
concavity of the adjacent liver surface. The abnormality is
moderately hyperintense in T2W images, isointense or slightly
hypointense in T1W, with a progressive and delayed enhance-
ment after contrast media administration (Fig. 9). Trapped
vessels and dilated biliary ducts can be seen within the
abnormality. On the cellular phase images after HBCM and
SPIO administration, the enhancement is usually decreased
due to cell necrosis. Internal focal areas of contrast pooling
correspond to residual functioning liver parenchyma.
Microscopic water diffusion is decreased in cirrhosis [2].
The reduced liver diffusion can be qualitatively observed on
the DW images (Fig. 10). Some studies have analyzed the role
of DW imaging, mainly throughout mean ADC comparisons,
in the evaluation of chronic diffuse liver diseases. Although
ADC measurements vary in b-values and motion correction
techniques, the ADC values of cirrhotic livers are significantly
lower. The shortest ADC values in cirrhosis are mainly related
to a decrease in the capillarity perfusion component and not to
a true microscopic diffusion restriction associated with fibrosis
and inflammation [25].
Taouli et al. evaluated DW technique as a predictor of the
presence of moderate and advanced liver fibrosis [26]. The
liver ADC value (breath hold, six b-values of 0, 50, 300, 500,
700 and 1,000 s/mm
2) in patients with chronic hepatitis versus
healthy volunteers was a significant predictor of fibrosis stage
F2 or greater and also stage F3 or greater. Similar results were
obtained by Lewin et al., where DW (navigator-triggered, four
b-values: 0, 200, 400, and 800 s/mm
2) was compared to other
non-invasive methods to conclude that patients with
moderate-to-severe fibrosis (F2-F3-F4) had hepatic ADC
values lower than those without or with mild fibrosis
(F0-F1) and healthy volunteers [22]. In discriminating patients
staged F3-F4, the sensitivity, specificity, positive predictive
value and negative predictive value were 87%, 87%, 72% and
94%, respectively, with an ADC cutoff level of 1.21×10-
3m m
2/s.
Fig. 9 Focal confluent fibrosis. STIR image shows a collapsed area
with capsular-based wedge shape. The abnormality is moderately
hyperintense in STIR (a) and shows progressive and delayed
enhancement after contrast media administration (b, arterial; c,
delayed phases)
Fig. 8 Fibrosis. Transverse fat suppression T1W spoiled GRE image
after administration of contrast media shows reticular pattern of the
fibrotic bands surrounding regenerative nodules
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diffusion properties by IVIM technique (respiratory
triggered, ten b-values: 0, 10, 20, 30, 50, 80, 100, 200,
400, 800 s/mm
2). They observed a restricted diffusion in
patients with cirrhosis mainly related to variations in the
perfusion component, reflecting decreased perfusion, as
well as alterations in pure molecular water diffusion in
cirrhotic livers [27]. Confirming this observation, Girometti
et al. (breath hold acquisition; six b-values: 0, 150, 250,
400, 600, 800 s/mm
2) also concluded that the perfusion
component presents a higher accuracy at lower b-values for
the assessment of liver fibrosis [28]. The studies in rats with
hepatic fibrosis, both in-vivo and immediately after death,
also pointed in this direction [25].
Although IVIM seems to be a promising technique in
the diagnosis and staging of fibrosis, some bias must be
clearly controlled to standardize this biomarker (Fig. 11).
The concomitant effect of MR machines, MR sequence
parameters, fat, iron, inflammation and necrosis on the
ADC values should be evaluated.
Cirrhotic liver vascular perfusion changes are related to
the disease activity and staging [2]. Although the arterial
blood supply is increased due to the decreased portal flow,
the buffer is not sufficient to maintain adequate liver
perfusion because of the high level of extrahepatic
portosystemic shunting. The overall reduction of the total
liver perfusion can be quantified as a prolongation of the
mean transit time and a decrease in mean peak liver
enhancement.
Another phenomenon is observed as fibrosis development
leads to progressive arterializations of the hepatic sinusoidal
bed, with shunting and hyperdynamic circulation, and aug-
mentation of the extracellular interstitial space with collagen
deposition. These changes produce an overall increase of the
liver enhancement during the equilibrium phase images of the
dynamic series. Some parametric pixel-by-pixel mapping, such
as the mean and maximum enhancement ratios, show
significantly higher values in cirrhosis than in normal livers
[16]. An increase in the liver enhancement can also be also
quantified with the area under the curve and is statistically
related to the degree of chronic hepatic insufficiency. A dual-
input single compartment model demonstrates an increased
distribution volume (related to the increased interstitial
volume) and mean transit time (related to the collagen
deposition in the extracellular spaces of Disse) [29].
Fig. 11 Fibrosis. IVIM parametric maps of pure diffusion (a, d),
perfusion (b, d*) and vascular components (c, f) of the diffusion-
related signal attenuation
Fig. 10 Fibrosis. Transverse signal video inversion of the diffusion-
weighted image shows decreased water diffusion in a patient with
liver cirrhosis
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objectively evaluated through the pharmacokinetic compart-
ment model analyses. Although the experience is limited,
cirrhotic livers have an increased vascular permeability (K
trans)
and extracellular space (υe) with a heterogeneous distribution.
These parameters correlate with the degree of liver fibrosis
and may be used as a hemodynamic biomarker in injured
fibrotic livers.
MRelastographyusesasoundwavegeneratorappliedtothe
patient [30]. The shear mechanical compressional waves are
transmitted through the liver, detected with phase-contrast
type sequences, and analyzed as wave propagation and tissue
deformation. The calculated elasticity maps show the shear
elasticity modulus (kPa) at each point. Quantitative stiffness
parametric maps, also known as elastograms, become more
heterogeneous with increasing fibrosis. Liver stiffness
increases as the stage of fibrosis advances. While differences
in stiffness between patients with early stages of fibrosis (F0
vs. F1 vs. F2) are small, with overlap between groups, the
differences between higher stages (F2 vs. F3 vs. F4) are larger
with less overlap [31].
MR spectroscopy enables the in vivo noninvasive quantiza-
tion of some biochemical compounds. Single voxel proton
hepatic MR spectroscopy can be obtained with sufficient
quality. Glutamine and glutamate complex (Glx), phosphomo-
noesters (PME), glycogen and glucose complex (Glyu), and
lipids are clearly observed. Chronic hepatitis and cirrhosis
showed an increase in Glx, PME and Glyu levels relative to the
lipid content. This increase is related to the severity of fibrosis,
although data overlap is present between groups [32].
Imaging vascular changes
Early fibrosis associates deposition of collagen in the Disse
space with alteration of the sinusoidal architecture, resulting
in a decreased portal venous flow, which is counteracted by
an increase in hepatic arterial flow (buffer response). When
the venous inflow blockade occurs and vascular resistance
increases, the portal flow may be adequate for centrally
located parenchyma areas, but not for the subcapsular
regions. The arterial response may generate enhancement of
these peripheral zones with relative hypointensity in the
central perihilar areas.
On the contrary, as previously mentioned, there may also
be a heterogeneous pattern of slightly hypervascular behavior
within geographical areas due to the presence of necroin-
flammatory infiltrates and steatosis [33]. Other common
causes of perfusion abnormalities to be taken into consider-
ation in cirrhotic livers are related to spontaneous arterio-
portal shunts (Fig. 12), shunts associated with vascular
compression (HCC, inflammatory changes, biliary tree
dilatation) and portal occlusion [34].
Portal hypertension frequently complicates liver cirrho-
sis. Dilatation of the portal vein and its tributaries, and
extrahepatic collateral circulation, splenomegaly and ascites
are well-known findings. Esophageal and gastric varices,
paraumbilical, spleno-renal, retroperitoneal and puborectal
shunts are well visualized with contrast-enhanced MR
images and MIP projections (Fig. 13). MR images after
Gd administration depict esophageal varices in most (81%)
cases with a statistically significant relationship with the
endoscopic grading of the severity [35]. Vascular engorge-
ment of the mesenteric vessels may produce a pseudoo-
mental cake appearance. Gallbladder wall thickening is
associated with venous and lymphatic congestion in the
presence of portal hypertension and drainage difficulty [36].
A relatively small main portal vein in patients with cirrhosis
may indicate hepatofugal flow. Early arterial phase enhance-
ment of the portal vein has been also reported as a sign of
hepatofugal flow [37], although this finding is misleading as
the late arterial phase mixes with the early portal phase.
In most cases, perfusion abnormalities are easy to interpret
on the non-specific contrast media enhanced images as they
Fig. 12 Vascular changes: arterioportal shunts. Transverse fat
suppression T1W spoiled GRE image after administration of contrast
media shows small and non-encapsulated areas with enhancement in
the arterial phase (a), but without wash-out on the portal phase image
(b)
240 Insights Imaging (2010) 1:233–244have clearly defined and straight-line margins, corresponding
to a vascular territory, and normal vessels coursing through the
abnormality. When the portal flow is decreased or absent and
the arterial flow volume is increased, they are often seen as
hyperarterialization with fading or disappearance in the portal
and equilibrium phases [38].
Imaging biliary changes
Liver cirrhosis may result in peribiliary cysts. Cyst abnormal-
ities occur in the peribiliary tissue adjacent to the large
intrahepatic and extrahepatic ducts in association with severe
liver disease, and are usually asymptomatic [39]. These cysts
have variable size and morphology and represent cystic
dilatation of the extramural glands in the periductal connective
tissue. Peribiliary cysts show imaging findings of simple
cysts, with low signal intensity on T1W and high signal on
heavily T2W MR images (Fig. 14).
Primary sclerosing cholangitis (PSC) shows irregular intra-
and/or extrahepatic bile duct dilatation and stenosis along with
periportal T2W hyperintensity in the major portal tracts.
Cirrhosis from advanced PSC develops marked atrophy of the
posterior aspect of the right lobe and the lateral segment of the
left lobe with hypertrophy of the caudate lobe.
In primary biliary cirrhosis, intrahepatic bile ducts are
progressively destroyed because of chronic non-suppurative
cholangitis. On T2W images, a periportal hyperintensity,
especially at earlier stages of disease, may be seen [40].
Imaging fat
Cirrhotic livers may have an increase in fat content. Also,
steatosis and nonalcoholic steatohepatitis (NASH) lead to
fibrosis and cirrhosis [41]. Early detection and follow-up of
steatosis would facilitate a better diagnosis and intervention
before liver damage is irreversible [2]. A large number of
patients with NASH and chronic hepatitis may also present
increased iron content in the liver with all these factors
affecting the imaging signal characteristics.
Chemical shift T1W dual echo GRE images (Fig. 15)a l l o w
the qualitative diagnosis of steatosis [42]. For the quantitative
Fig. 14 Liver peribiliary cysts. MRCP image shows peribiliary cysts
with variable size and morphology
Fig. 13 Portal hypertension. MIP vascular image reconstructed from
the portal phase shows collaterals vessels and splenomegaly
Fig. 15 Liver steatosis. Transverse opposed-phase T1W image (a)
shows decreased signal intensity of liver, while in the axial in-phase
T1W image (b) the liver shows increased signal intensity
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opposed-phase images may be erroneous unless a correction
is made for the influence of T2* decay [43]. The T2W TSE
with and without fat suppression method is easier and accurate
enough in a clinical setting [44]. However, single voxel proton
MR spectroscopy, although limited by the volume sampling,
will be needed in clinical trials and longitudinal studies to
further increase accuracy.
Imaging iron
Cirrhosis is frequently associated with an increased depo-
sition of iron, mainly in alcoholic cirrhosis. Also, primary
iron overload may lead to cirrhosis. Conventional chemical
shift dual echo GRE T1W and TSE-STIR images will
demonstrate the liver signal intensity drop, allowing the
qualitative diagnosis of significant iron deposits (Fig. 16).
When iron has been demonstrated, a quantitative measure-
ment should be obtained.
Both the liver-to-muscle signal ratio and the liver R2*
relaxation rate significantly correlate with the amount of
Fig. 16 Liver iron overload. Transverse opposed-phase (a) and in-
phase (b) T1W images show a decrease in the signal intensity of the
liver in the in-phase image because of increased deposition of iron
Fig. 17 Hepatocellular carcinoma. Transverse T1W images (a,
opposed phase; b, in-phase) show a slightly hypointense encapsulated
lesion located in the right posteroinferior segment. The lesion is
hypervascular (c) with washout (d) with a delayed enhancing outer
rim capsule
242 Insights Imaging (2010) 1:233–244iron content [3, 4]. Although sequences and postprocessing
of images for T2 and T2* relaxation rate calculations are
more difficult to implement in a clinical environment, this
approach must be preferred to the simple signal-to-ratio
determination in clinical trials. The calibration between R2*
and iron concentration is dependent on field strength, being
different for 1.5- and 3-T magnets [45].
The coupling of multiecho GRE techniques with chemical
shift imaging may simultaneous l ye v a l u a t eb o t hi r o na n df a t
liver content [46]. This is relevant as both entities may coexist
in a significant number of cases with chronic liver disease.
Imaging neoplasia
Liver imaging evaluation in cirrhotic patients should also
search for tumor development [47]. Overt HCC is
characterized by a mass lesion showing hyperarterializa-
tion with washout, becoming hypointense to the liver on
the delayed phases after contrast administration (Fig. 17).
The presence of a capsule and internal mosaic appearance
are secondary criteria. Dysplasia, atypia and early neo-
plasic degeneration are much more difficult to demon-
strate. In this setting, any hyperintensity within a nodule in
the T2W images and hyperintense nodules in the T1W
images may be considered suspicious, and their perfusion
characteristics should be carefully evaluated. DW images
may help in depicting a malignant transformation if clear
diffusion restriction is observed.
Some special situations in cirrhotic livers need further
comment. Nodular appearance of arterio-portal shunts is
typically seen in cirrhosis as a small and non-
encapsulated area with ill-defined margins. They are not
seen on the plain non-contrast-enhanced images, delayed
equilibrium and cellular phases after HBCM and reticu-
loendothelial system contrast media (RECM), allowing
the differentiation with small HCC.
To differentiate a nodular arterio-portal shunt from a
small HCC without washout on the equilibrium phase
images, specific contrast media (either HBCM or SPIO)
can be useful if no significantly different uptake is seen,
a finding typical of arterio-portal shunt. A transient
hepatic arterialization may highlight a small HCC
determining portal compression. This is also the situation
with peribiliary transient hepatic arterialization caused by
long-standing biliary obstruction.
Conclusion
The typical histological features of chronic hepatitis and
cirrhosis influence the liver’s appearance and must be
assessed separately by imaging biomarkers in order to be
useful clinically. With advancements in MR technologi-
cal quantification, several biomarkers have been devel-
oped to grade the liver status in cirrhosis. Nowadays,
research is focused on developing ways to improve
detection of early and intermediate stages of fibrosis as
well as hepatocyte dysfunction. The implementation of
these biomarkers in a clinical environment is still waiting
on an appropriate evaluation of their diagnostic accuracy.
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